Viral hepatitis in 2003

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Current Opinion in Gastroenterology

• Publication date

  2004-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00001574-200405000-00008PMID 15703648
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.

  2003cited by this paper
• Prevalence of HBV precore/core promoter variants in the United States

  2003cited by this paper
• Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B

  2003cited by this paper
• A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C

  2003cited by this paper
• An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

  2003cited by this paper
• Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C

  2003cited by this paper
• High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C

  2003cited by this paper
• Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

  2003cited by this paper
• An NS 3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

  2003cited by this paper
• Progression of fibrosis in chronic hepatitis C.

  2003cited by this paper
• Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C

  2003cited by this paper
• Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease

  2003cited by this paper
• Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT

  2003cited by this paper
• Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

  2003cited by this paper
• Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

  2003cited by this paper
• Long‐Term suppression of hepatitis B e antigen‐negative chronic hepatitis B by 24‐month interferon therapy

  2003cited by this paper
• Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients

  2003cited by this paper
• Outcomes of interferon α and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases

  2003cited by this paper
• Hepatitis B virus genotypes in the United States: results of a nationwide study.

  2003cited by this paper
• Sampling variability of liver fibrosis in chronic hepatitis C

  2003cited by this paper
• Favorable prognosis of chronic hepatitis C after interferon therapy by long‐term cohort study

  2003cited by this paper
• Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C.

  2003cited by this paper
• Durability of serologic response after lamivudine treatment of chronic hepatitis B

  2003cited by this paper
• Viramidine, a Prodrug of Ribavirin, Shows Better Liver-Targeting Properties and Safety Profiles Than Ribavirin in Animals

  2003cited by this paper
• Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.

  2003cited by this paper
• Determinants for sustained HBeAg response to lamivudine therapy

  2003cited by this paper
• Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients

  2003cited by this paper
• Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

  2003cited by this paper
• Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

  2003cited by this paper
• Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core‐related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment

  2003cited by this paper
• Histological outcome during long-term lamivudine therapy.

  2003cited by this paper
• Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease.

  2003cited by this paper
• Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B

  2003cited by this paper
• Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa‐2b and ribavirin

  2003cited by this paper
• Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

  2002cited by this paper
• Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

  2002cited by this paper
• Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy

  2002cited by this paper
• Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.

  2002cited by this paper
• Hepatitis B Virus of Genotype B with or without Recombination with Genotype C over the Precore Region plus the Core Gene

  2002cited by this paper
• Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

  2001cited by this paper
• Treatment of acute hepatitis C with interferon alfa-2b.

  2001cited by this paper
• Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B

  2001cited by this paper
• Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

  2000cited by this paper
• A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness.

  2000cited by this paper
• Relationships within and between genotypes of hepatitis B virus at points across the genome: footprints of recombination in certain isolates.

  2000cited by this paper
• Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C – a study of 527 patients at one establishment

  2000cited by this paper
• Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C

  2000cited by this paper
• Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey

  2000cited by this paper
• Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin.

  1999cited by this paper
• Long term response to therapy of chronic anti-HBe–positive Hepatitis B is poor independent of type and schedule of interferon

  1999cited by this paper
• Clinical features of hepatitis C–infected patients with persistently normal alanine transaminase levels in the southwestern United States

  1999cited by this paper
• Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.

  1999cited by this paper
• Prognosis of chronic hepatitis c: Results of a large, prospective cohort study

  1998cited by this paper
• Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: A pilot randomized controlled study

  1998cited by this paper
• Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

  1998cited by this paper
• Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

  1997cited by this paper
• Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus--large-scale analysis using a new genotyping method.

  1997cited by this paper
• Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases.

  1995cited by this paper
• Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes.

  1994cited by this paper
• Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group.

  1994cited by this paper
• Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C

  1994cited by this paper
• A 21-year experience with major hemorrhage after percutaneous liver biopsy.

  1990cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Target-binding behavior of IDPs via pre-structured motifs.

  2021cites this paper
• The unique role of the hepatitis virus B X protein on HEK 293 cell morphology and cellular change

  2016cites this paper
• Dioscin's antiviral effect in vitro.

  2013cites this paper
• Serología en hepatitis virales

  2010cites this paper
• An anti-viral peptide derived from the preS1 surface protein of hepatitis B virus.

  2008cites this paper
• Pre‐structured motifs in the natively unstructured preS1 surface antigen of hepatitis B virus

  2007cites this paper
• A flavonoid from medicinal plants blocks hepatitis B virus-e antigen secretion in HBV-infected hepatocytes.

  2005cites this paper
• Subtypes of hepatitis B surface antigen in Turkey.

  2005cites this paper
• The ABCs of hepatitis.

  2005cites this paper